A case report of telitacicept in the treatment of immunocompromised and refractory lupus nephritis
Abstract
Lupus nephritis (LN) is a manifestation of kidney damage in systemic lupus erythematosus and is more common in Asian populations. The standard-of-care (SOC) for LN includes antimalarials, glucocorticoids, and immunosuppressants. The efficacy and safety of biologics have been validated, and they play an important role in the treatment of LN. This case report describes a patient with immunocompromised refractory LN who had repeated severe infections after SOC and visited the clinic for recurrence of LN combined with pneumonia. The patient was admitted to the hospital this time due to “recurrent rash for 15 years, edema for 2 years, and aggravation for 1 month”. After anti-infective therapy, the treatment plan for glucocorticoids combined with telitacicept was individualized based on the patient’s immune status, and the disease was quickly controlled. Simultaneously, it demonstrated efficacy and safety during follow-up, suggesting that telitacicept may be a new treatment option for refractory LN.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.